CA2951909C - Self-assembled residence devices and related methods - Google Patents

Self-assembled residence devices and related methods Download PDF

Info

Publication number
CA2951909C
CA2951909C CA2951909A CA2951909A CA2951909C CA 2951909 C CA2951909 C CA 2951909C CA 2951909 A CA2951909 A CA 2951909A CA 2951909 A CA2951909 A CA 2951909A CA 2951909 C CA2951909 C CA 2951909C
Authority
CA
Canada
Prior art keywords
structures
residence device
attachment
residence
attachment point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2951909A
Other languages
English (en)
French (fr)
Other versions
CA2951909A1 (en
Inventor
Andrew BELLINGER
Shiyi ZHANG
Carlo Giovanni TRAVERSO
Robert S. Langer
Stacy MO
Jiaqi Lin
Angela DICICCIO
Dean Liang Glettig
Lowell L. Wood Jr.
Philip A. Eckhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Original Assignee
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2951909(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc, Massachusetts Institute of Technology filed Critical Brigham and Womens Hospital Inc
Publication of CA2951909A1 publication Critical patent/CA2951909A1/en
Application granted granted Critical
Publication of CA2951909C publication Critical patent/CA2951909C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
    • C08G18/4269—Lactones
    • C08G18/4277—Caprolactone and/or substituted caprolactone
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
    • C08L33/08—Homopolymers or copolymers of acrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Prostheses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2951909A 2014-06-11 2015-06-11 Self-assembled residence devices and related methods Active CA2951909C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010992P 2014-06-11 2014-06-11
US62/010,992 2014-06-11
PCT/US2015/035429 WO2015191925A1 (en) 2014-06-11 2015-06-11 Self-assembled residence devices and related methods

Publications (2)

Publication Number Publication Date
CA2951909A1 CA2951909A1 (en) 2015-12-17
CA2951909C true CA2951909C (en) 2022-08-16

Family

ID=54834353

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2951909A Active CA2951909C (en) 2014-06-11 2015-06-11 Self-assembled residence devices and related methods
CA2951884A Pending CA2951884A1 (en) 2014-06-11 2015-06-11 Residence structures and related methods
CA2951902A Active CA2951902C (en) 2014-06-11 2015-06-11 Enteric elastomers

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2951884A Pending CA2951884A1 (en) 2014-06-11 2015-06-11 Residence structures and related methods
CA2951902A Active CA2951902C (en) 2014-06-11 2015-06-11 Enteric elastomers

Country Status (19)

Country Link
US (16) US10413507B2 (OSRAM)
EP (5) EP3725357B1 (OSRAM)
JP (9) JP2017519003A (OSRAM)
KR (2) KR102704895B1 (OSRAM)
CN (4) CN106573999A (OSRAM)
AU (6) AU2015274451C1 (OSRAM)
BR (2) BR122021018078B1 (OSRAM)
CA (3) CA2951909C (OSRAM)
DK (2) DK3155024T4 (OSRAM)
ES (2) ES2832334T5 (OSRAM)
FI (2) FI3725357T3 (OSRAM)
IL (1) IL249435B (OSRAM)
MX (2) MX2016016406A (OSRAM)
NZ (1) NZ727659A (OSRAM)
PL (1) PL3725357T3 (OSRAM)
RU (1) RU2766335C2 (OSRAM)
SG (2) SG10201912100SA (OSRAM)
WO (3) WO2015191925A1 (OSRAM)
ZA (1) ZA201608889B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948557A (zh) 2014-04-08 2014-07-30 闻晓光 一种新型控释片
CN106535878B (zh) 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
CN106573999A (zh) * 2014-06-11 2017-04-19 麻省理工学院 驻留结构及相关方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN107438404B (zh) 2014-09-25 2021-07-20 普罗根尼蒂公司 具有定位能力的机电药丸设备
CN107592803B (zh) * 2015-05-01 2021-01-22 麻省理工学院 可触发形状记忆感应装置
US10939865B2 (en) * 2015-10-06 2021-03-09 Ligalli B.V. Vaginal drug delivery device and vaginal diagnostic device
EP3153137A1 (en) * 2015-10-06 2017-04-12 Li Galli B.V. Vaginal drug delivery device and vaginal diagnostic device
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108601724A (zh) * 2015-12-01 2018-09-28 克雷西奥生物科技有限公司 胃滞留装置
ES2963058T3 (es) * 2015-12-08 2024-03-25 Lyndra Therapeutics Inc Configuraciones geométricas para sistemas de residencia gástrica
JP7665280B2 (ja) 2015-12-22 2025-04-21 アクセス・バスキュラー・インコーポレイテッド 高強度生体材
US10470799B2 (en) * 2016-04-21 2019-11-12 Massachusetts Institute Of Technology Origami robots, systems, and methods of treatment
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
AU2017322324B2 (en) 2016-09-09 2022-11-24 Bt Bidco, Inc. Electromechanical ingestible device for delivery of a dispensable substance
WO2018064630A1 (en) * 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP3320898A1 (en) 2016-11-11 2018-05-16 ratiopharm GmbH Dosage form comprising a carrier structure and method for manufacturing the dosage form
CN110035718B (zh) * 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3597258B1 (en) * 2017-03-16 2025-09-03 Terumo Kabushiki Kaisha Catheter assembly
IL268900B2 (en) 2017-03-31 2023-11-01 Biora Therapeutics Inc Localization systems and methods for an ingestible device
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
AU2018269711B2 (en) 2017-05-17 2023-07-27 Massachusetts Institute Of Technology Self-righting systems and related components and methods
US12023406B2 (en) 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
WO2018237166A1 (en) 2017-06-21 2018-12-27 Access Vascular, Inc High strength porous materials incorporating water soluble polymers
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
CN107773554A (zh) * 2017-09-07 2018-03-09 华南农业大学 一种伊维菌素缓释微囊及其制备方法和应用
EP3684321B1 (en) * 2017-09-20 2024-12-25 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
WO2019083483A2 (en) * 2017-10-11 2019-05-02 Ege Universitesi A vaginal implant
TWI837082B (zh) * 2017-11-22 2024-04-01 美商萊恩卓治療公司 用於胃滯留系統之材料架構
EP3716850A1 (en) * 2017-11-28 2020-10-07 Massachusetts Institute of Technology Gastric resident electronics
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
AU2019269636A1 (en) 2018-05-17 2020-11-19 Massachusetts Institute Of Technology Systems for electrical stimulation
US20190365645A1 (en) * 2018-05-31 2019-12-05 Massachusetts Institute Of Technology Drug delivery articles for gram-level dosing
AU2019321648A1 (en) * 2018-08-15 2021-03-18 Lyndra Therapeutics, Inc. Systems for enteric delivery of therapeutic agents
WO2020102629A1 (en) * 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Thermally controlled residence devices
WO2020102650A2 (en) 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Thermally controlled reconfigurable medical devices
WO2020101737A1 (en) * 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Actuating components and related methods
JP7482866B2 (ja) * 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
JP2022514368A (ja) 2018-12-19 2022-02-10 アクセス・バスキュラー・インコーポレイテッド 放出制御用高強度多孔質材料
EP3917598B1 (en) 2019-02-01 2025-10-29 Massachusetts Institute of Technology Systems for liquid injection
CA3134049A1 (en) * 2019-03-20 2020-09-24 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
BR112021018424A2 (pt) * 2019-03-20 2021-11-23 Lyndra Therapeutics Inc Revestimentos para formas de dosagem de residência gástrica
WO2020257017A1 (en) * 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN110591125B (zh) * 2019-07-31 2021-01-26 北京理工大学 一种可溶解的三维交联弹性体及其制备和处理方法
CN119733161A (zh) * 2019-10-01 2025-04-01 拉尼医疗有限公司 用于将制剂递送到管腔壁的自定尺寸装置
US20220387312A1 (en) * 2019-11-08 2022-12-08 Lyndra Therapeutics, Inc. Gastric residence systems having arms with controlled stiffness for improved gastric residence
CN114938634A (zh) * 2019-11-08 2022-08-23 林德拉治疗公司 用于胃驻留系统的释放速率调节膜的配方
WO2021092491A1 (en) * 2019-11-08 2021-05-14 Lyndra, Inc. Gastric residence systems for administration of active agents
US20230190941A1 (en) * 2019-11-08 2023-06-22 Lyndra Therapeutics, Inc. Polymeric linkers for a gastric residence system
EP4054538A4 (en) * 2019-11-08 2024-02-07 Lyndra Therapeutics, Inc. STOMACH RESIDENCE SYSTEMS WITH A FILAMENT FOR IMPROVED STOMACH RESIDENCE
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4114493A4 (en) * 2020-03-06 2024-04-10 Access Vascular, Inc. PACKAGING FOR HYDROGENATED ARTICLES AND RELATED PROCESSES
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
WO2021231411A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology Gastroretentive articles for alcohol sensing
WO2022006000A1 (en) 2020-06-30 2022-01-06 Access Vascular, Inc. Articles comprising markings and related methods
JP2023536456A (ja) * 2020-07-29 2023-08-25 ザ・セカント・グループ・エルエルシー 架橋ポリ（セバシン酸グリセロール）を含む構造を含む形状誘導型制御放出および保持
US20240252483A1 (en) * 2021-05-05 2024-08-01 Lyndra Therapeutics, Inc. Gastric residence systems comprising buprenorphine and naloxone
WO2023021480A1 (en) 2021-08-19 2023-02-23 Clexio Biosciences Ltd. Method of treating parkinson's disease
IL319899A (en) * 2022-09-30 2025-05-01 Lyndra Therapeutics Inc Risperidone dosing regimens with gastric retention systems
WO2024081793A1 (en) 2022-10-12 2024-04-18 Massachusetts Institute Of Technology Ingestible in vivo-assembling drug release formulations and methods
WO2024249946A2 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025090468A1 (en) * 2023-10-24 2025-05-01 Soane Pharma LLC Orally ingestible delivery system
CN119971273A (zh) * 2024-01-09 2025-05-13 厦门君德医药科技有限公司 一种胃滞留装置
KR20250121713A (ko) * 2024-02-05 2025-08-12 재단법인대구경북과학기술원 장내 생물학적 물질 다중 채취를 위한 채취 모듈 전달 캡슐
US20250295901A1 (en) * 2024-03-19 2025-09-25 Lyndra Therapeutics, Inc. Flexible line configurations for gastric residence systems
WO2025195482A1 (zh) * 2024-03-22 2025-09-25 厦门君德医药科技有限公司 一种胃滞留装置
WO2025222033A1 (en) * 2024-04-18 2025-10-23 The Regents Of The University Of California Time-controlled payload release capsules

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US415671A (en) * 1889-11-19 harris
US3154461A (en) 1960-03-07 1964-10-27 Minnesota Mining & Mfg Matte-finish polymeric film and method of forming the same
AU449029B2 (en) 1969-08-28 1974-04-17 Commonwealth Scientific And Industrial Research Organisation Device for administration to ruminants
JPS5512411B2 (OSRAM) 1974-03-12 1980-04-02
US4199561A (en) * 1979-02-26 1980-04-22 The Dow Chemical Company Coated nutrients and medicaments for veterinary use
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4676507A (en) 1985-05-06 1987-06-30 Patterson Bruce D Puzzles forming platonic solids
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPS6226215A (ja) * 1985-05-10 1987-02-04 メルク　エンド　カムパニ−　インコ−ポレ−テツド 一定に制御した時間内胃中に保持できる薬剤移送装置
CA1273872A (en) † 1985-05-10 1990-09-11 Larry J. Caldwell Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
EP0253554A3 (en) * 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
EP0406315B1 (en) 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ228382A (en) * 1989-03-17 1992-08-26 Carter Holt Harvey Plastic Pro Drug administering coil-like device for insertion in body cavity of animal
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US5047464A (en) * 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5369142A (en) * 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
WO1995003558A1 (en) * 1993-07-19 1995-02-02 Reflexite Corporation Retroreflective structure
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US6962579B2 (en) 1995-03-23 2005-11-08 Advanced Animal Technology Limited Substance delivery device
DE69624227T2 (de) 1995-03-23 2003-06-12 Advanced Animal Technology Ltd., Hamilton Substanzabgabevorrichtung
TW354451B (en) 1995-09-18 1999-03-11 Ibm Method of fabricating cross-linked biobased materials and structures fabricated therewith a method comprising the step of: forming the mixture of polymer and cross-linked agent
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
WO1997038969A1 (en) * 1996-04-12 1997-10-23 Japan Atomic Energy Research Institute pH-SENSITIVE POLYMERS
GB9616267D0 (en) 1996-08-02 1996-09-11 Ranier Ltd Balloon catheter
DE69828289T2 (de) 1997-08-11 2005-06-02 Alza Corp., Mountain View Dosierungsform für verzögerte Freisetzung eines Wirkstoffs
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US20020022048A1 (en) 2000-05-26 2002-02-21 Bromberg Lev E. Composite wafer for controlled drug delivery
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US6627206B2 (en) * 2001-07-25 2003-09-30 Greg A. Lloyd Method and apparatus for treating obesity and for delivering time-released medicaments
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
BR0117123A (pt) 2001-08-16 2004-09-28 Oregon State Dispositivo de retenção gástrica expansìvel
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
KR100417163B1 (ko) 2001-11-12 2004-02-05 한국과학기술연구원 마이크로 캡슐형 로봇
US20050165136A1 (en) 2002-01-23 2005-07-28 Uab Research Foundation Glass-ionomer cements containing amino acids
WO2003089506A1 (en) * 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10224352A1 (de) 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
TWI336260B (en) 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
AU2003282603A1 (en) 2002-10-11 2004-05-04 Depomed Development Ltd Gastro-retentive levodopa delivery form
CA2516285A1 (en) * 2003-02-19 2004-09-02 Mnemoscience Gmbh Self-expanding device for the gastrointestinal or urogenital area
JP4497833B2 (ja) * 2003-04-21 2010-07-07 富士フイルム株式会社 ポジ型平版印刷版原版
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
BRPI0411437B8 (pt) 2003-06-13 2021-06-22 Gkss Forschungszentrum Geesthacht Gmbh stent para uso no campo não-vascular ou vascular, método para sua fabricação e kit compreendendo esse stent
EP1638533A1 (en) 2003-06-18 2006-03-29 John Michael Newton Controlled release devices with lumens
US8048169B2 (en) * 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US6825308B1 (en) * 2003-10-29 2004-11-30 Council Of Scientific And Industrial Research Copolymers and preparation thereof
CA2549195A1 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
AU2005287383B2 (en) * 2004-05-25 2011-09-22 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
DE102004047076A1 (de) * 2004-09-28 2006-04-06 Zimmer Ag Verfahren zur Herstellung von Polyestern
IL166183A0 (en) 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
RU2411045C2 (ru) * 2005-01-27 2011-02-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Ран Гидрофильные биологически совместимые адгезивные композиции и их применение
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
US7699863B2 (en) * 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7785291B2 (en) * 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2006323082A (ja) 2005-05-18 2006-11-30 Canon Inc 現像剤補給容器
US8021384B2 (en) 2005-07-26 2011-09-20 Ram Weiss Extending intrabody capsule
CN101175571A (zh) 2005-08-05 2008-05-07 滋贺县 含有共混聚合物而成的液体中物质转移材料
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
WO2007048223A2 (en) 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
WO2007072495A2 (en) * 2005-11-03 2007-06-28 Sun Pharmaceutical Industries Limited Coated tablets having prolonged gastric retention
US7674396B2 (en) 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
TR201902010T4 (tr) 2006-01-18 2019-03-21 Intec Pharma Ltd Bir ajanın oral alımına yönelik taşıyıcı cihaz.
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US20090246142A1 (en) * 2006-03-10 2009-10-01 Massachusetts Institute Of Technology Triggered Self-Assembly of Nanoparticles In Vivo
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CA2661172A1 (en) 2006-09-04 2008-05-29 Panacea Biotec Limited Programmable buoyant delivery technology
US20080075766A1 (en) 2006-09-25 2008-03-27 Shun-Por Li Multi-core dosage form having transparent outer coating
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008140651A2 (en) 2007-03-13 2008-11-20 Olson Arthur J Self-assembled polyhedra
US20100297009A1 (en) * 2007-03-13 2010-11-25 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
JP2010527712A (ja) * 2007-05-25 2010-08-19 ゴーラム エンタープライゼス エルエルシー 肥満症用の磁気装置およびその製造方法
US8038659B2 (en) * 2007-10-17 2011-10-18 The Invention Science Fund I, Llc Disintegrating digestive tract interaction system
US8303573B2 (en) * 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20130273135A1 (en) 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
EP2276473B1 (en) 2008-04-18 2016-09-14 Intec Pharma Ltd. Gastroretentive drug delivery for carbidopa/levodopa
WO2009132461A1 (en) 2008-04-28 2009-11-05 Electronic Dietary Foods Inc. Bezoar-forming units for weight control
US20100256342A1 (en) * 2008-08-12 2010-10-07 Francis Raymond Salemme Protein nodes for controlled nanoscale assembly
KR20110042366A (ko) 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
PL2349222T3 (pl) 2008-09-10 2017-08-31 Sandoz Ag Kapsułka z rozpuszczalnym elementem blokującym
WO2010035273A2 (en) 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
CA2746989A1 (en) * 2008-12-27 2010-07-01 Chandra S. Duggirala Devices for treating obesity and methods of using those devices
US9845237B2 (en) * 2009-02-26 2017-12-19 The Regents Of The University Of California Supramolecular approach for preparation of size controllable nanoparticles
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
DE102009028076A1 (de) * 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US20110052497A1 (en) * 2009-08-27 2011-03-03 Taris Biomedical, Inc. Minimally Invasive Systems and Methods for In Vivo Testing of Materials
US20110052700A1 (en) 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
WO2011032087A2 (en) 2009-09-11 2011-03-17 Replication Medical Inc. Swellable polymeric device for dietary regulation
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US9421169B2 (en) 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
CN101711752B (zh) 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
ES2804716T3 (es) * 2009-12-24 2021-02-09 Rani Therapeutics Llc Dispositivo tragable para la administración de fármacos
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
WO2011139796A2 (en) 2010-04-27 2011-11-10 The Johns Hopkins University Self-folding sub-centimeter structures
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US20120165794A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165793A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US9107816B2 (en) 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
EP2764557A4 (en) * 2011-09-26 2016-04-27 Univ Northeastern CUSTOMIZABLE INTEGRATED SENSORS
US8835507B2 (en) 2012-02-21 2014-09-16 Vymed Corporation Adamantane derivatives possessing anti-viral and anti-microbial activity
US8979887B2 (en) 2012-02-24 2015-03-17 Elwha Llc Devices, systems, and methods to control stomach volume
CA2879282C (en) 2012-07-16 2022-05-03 Hendrik Jan Cornelis Meijerink Gastro-retentive drug delivery system
US9307966B2 (en) 2012-08-15 2016-04-12 St. Jude Medical Puerto Rico Llc Vascular closure device anchor
RU2015107517A (ru) 2012-08-16 2016-10-10 Тева Фармасьютикал Индастриес Лтд. Фармацевтические композиции мемантина
US8746339B2 (en) * 2012-09-27 2014-06-10 Halliburton Energy Services, Inc. Triggerable lost circulation material and method of use
US10441760B2 (en) 2013-03-01 2019-10-15 The Johns Hopkins University Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
CN103654903A (zh) * 2013-11-27 2014-03-26 西安交通大学 一种用于人体消化道吻合的磁性可降解装置
AU2014358675B2 (en) 2013-12-05 2019-10-03 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
WO2015168297A1 (en) 2014-04-29 2015-11-05 Massachusetts Institute Of Technology Polymeric materials for bio-applications
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN106535878B (zh) † 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
CN106573999A (zh) 2014-06-11 2017-04-19 麻省理工学院 驻留结构及相关方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN107592803B (zh) 2015-05-01 2021-01-22 麻省理工学院 可触发形状记忆感应装置
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
ES2963058T3 (es) 2015-12-08 2024-03-25 Lyndra Therapeutics Inc Configuraciones geométricas para sistemas de residencia gástrica
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
WO2018064630A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
US20240390270A1 (en) * 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone

Also Published As

Publication number Publication date
US20200085736A1 (en) 2020-03-19
BR112016028957A2 (pt) 2017-08-22
US20190175500A1 (en) 2019-06-13
WO2015191922A1 (en) 2015-12-17
AU2015274451C1 (en) 2019-09-12
JP6666858B2 (ja) 2020-03-18
US11389399B2 (en) 2022-07-19
FI3725357T3 (fi) 2024-12-13
US20230039421A1 (en) 2023-02-09
DK3725357T3 (da) 2024-12-09
AU2015274451A1 (en) 2017-01-12
DK3155024T3 (da) 2020-11-23
RU2766335C2 (ru) 2022-03-15
US10517820B2 (en) 2019-12-31
EP3725357A1 (en) 2020-10-21
CN106714893B (zh) 2021-01-01
JP2017519003A (ja) 2017-07-13
AU2015274453A1 (en) 2017-01-12
JP2020056042A (ja) 2020-04-09
AU2015274451B2 (en) 2019-06-20
JP2025041821A (ja) 2025-03-26
AU2021203086A1 (en) 2021-06-10
KR102704895B1 (ko) 2024-09-11
US10532027B2 (en) 2020-01-14
AU2015274456B2 (en) 2020-03-26
US20210177750A1 (en) 2021-06-17
CA2951902C (en) 2022-08-23
WO2015191925A8 (en) 2016-02-11
SG11201610246PA (en) 2017-01-27
ES3001020T3 (es) 2025-03-04
US10716751B2 (en) 2020-07-21
US20190133936A1 (en) 2019-05-09
US20190070107A1 (en) 2019-03-07
CN106573015B (zh) 2021-11-26
JP7405820B2 (ja) 2023-12-26
US10182985B2 (en) 2019-01-22
CA2951902A1 (en) 2015-12-17
KR20220162852A (ko) 2022-12-08
FI3155024T4 (fi) 2025-07-28
EP4516322A8 (en) 2025-04-16
RU2017100273A3 (OSRAM) 2018-11-12
US10849853B2 (en) 2020-12-01
JP7337746B2 (ja) 2023-09-04
US11246829B2 (en) 2022-02-15
US20210113460A1 (en) 2021-04-22
JP6681390B2 (ja) 2020-04-15
US20190298652A1 (en) 2019-10-03
US20200085737A1 (en) 2020-03-19
AU2015274456A1 (en) 2017-01-12
JP2017519098A (ja) 2017-07-13
JP2020114874A (ja) 2020-07-30
SG10201912100SA (en) 2020-02-27
CA2951909A1 (en) 2015-12-17
AU2015274453A2 (en) 2017-01-19
KR102471095B1 (ko) 2022-11-28
KR20170016960A (ko) 2017-02-14
RU2017100273A (ru) 2018-07-11
US20170135954A1 (en) 2017-05-18
CN106573999A (zh) 2017-04-19
EP3155024A1 (en) 2017-04-19
AU2020200346A1 (en) 2020-02-06
MX2016016406A (es) 2017-10-12
EP3154622A4 (en) 2018-01-17
JP7629898B2 (ja) 2025-02-14
CN106714893A (zh) 2017-05-24
IL249435A0 (en) 2017-02-28
US11357723B2 (en) 2022-06-14
US20200030234A1 (en) 2020-01-30
US20210128460A1 (en) 2021-05-06
EP3154553A4 (en) 2018-03-28
US20170106099A1 (en) 2017-04-20
CA2951884A1 (en) 2015-12-17
IL249435B (en) 2020-08-31
EP3155024A4 (en) 2018-01-17
EP3155024B1 (en) 2020-09-16
US11077056B2 (en) 2021-08-03
EP3155024B2 (en) 2025-06-18
ES2832334T5 (en) 2025-09-24
EP3154622A1 (en) 2017-04-19
ES2832334T3 (es) 2021-06-10
PL3725357T3 (pl) 2025-03-03
US10413507B2 (en) 2019-09-17
AU2019232862A1 (en) 2019-10-10
MX2023005223A (es) 2023-05-16
JP2023022316A (ja) 2023-02-14
JP2017524662A (ja) 2017-08-31
EP3154622B1 (en) 2020-04-01
US20190070108A1 (en) 2019-03-07
EP3725357B1 (en) 2024-11-13
JP2022031924A (ja) 2022-02-22
BR122021018078B1 (pt) 2022-02-08
US10716752B2 (en) 2020-07-21
US10610482B2 (en) 2020-04-07
EP3154553B1 (en) 2020-08-05
ZA201608889B (en) 2022-04-28
CN106573015A (zh) 2017-04-19
WO2015191925A1 (en) 2015-12-17
EP4516322A2 (en) 2025-03-05
AU2020200346B2 (en) 2021-08-05
CN116370644A (zh) 2023-07-04
AU2021203086B2 (en) 2023-02-23
NZ727659A (en) 2021-12-24
BR112016028957B1 (pt) 2021-12-14
EP3154553A1 (en) 2017-04-19
WO2015191920A1 (en) 2015-12-17
EP4516322A3 (en) 2025-05-14
WO2015191920A8 (en) 2016-02-04
JP2020097623A (ja) 2020-06-25
US10517819B2 (en) 2019-12-31
DK3155024T4 (da) 2025-07-21
US20170128576A1 (en) 2017-05-11
US20210093564A1 (en) 2021-04-01
US11083690B2 (en) 2021-08-10

Similar Documents

Publication Publication Date Title
JP7405820B2 (ja) 自己集合滞留デバイスおよび関連方法
US20170266112A1 (en) Residence structures and related methods
HK1235722B (en) Self-assembled residence devices and related methods
HK1235722A1 (en) Self-assembled residence devices and related methods
HK40121345A (en) Residence structures and related methods
HK40036859A (en) Residence structures and related methods
HK1235418A1 (en) Residence structures and related methods
HK1235418B (en) Residence structures and related methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200611

EEER Examination request

Effective date: 20200611

EEER Examination request

Effective date: 20200611